Chimerix Announces Appointment of M. Michelle Berrey, M.D., M.P.H. as Chief Executive Officer
GlobeNewswire - Wed Apr 09, 8:22AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of M. Michelle Berrey, M.D., M.P.H. to the position of President and Chief Executive Officer. Dr. Berrey succeeds Kenneth I. Moch following his resignation from that role to pursue other interests. In addition, Dr. Berrey will continue to serve as Chimerix's Chief Medical Officer.
Increased Earnings Estimates Seen for Chimerix (CMRX): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 8:20AM CDT
Stock of Chimerix looks promising, as it is seeing solid activity on the earnings estimate revision front
3 Stocks That Escaped Biotech's March Madness
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but there were a few biotech stocks that soared. Among them were Agios Pharmaceuticals , Chimerix, Inc. , and Portola Pharmaceuticals . All three shrugged off the broad biotech sell-off that...
Chimerix Appoints Lisa Ricciardi to Board of Directors
GlobeNewswire - Tue Apr 01, 6:00AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Lisa Ricciardi to the Company's Board of Directors.
Chimerix to Present a Summary of Brincidofovir's (CMX001) Hematologic Safety at the Annual Meeting of the European Group for Blood and Marrow Transplantation
GlobeNewswire - Mon Mar 24, 3:15PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced an upcoming presentation on its investigational broad-spectrum antiviral brincidofovir (CMX001) at the 40 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) being held March 30 - April 2, 2014 in Milan, Italy.
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Chimerix Issues Statement Thanking the FDA for Collaboration in Developing Protocol to Treat Patients With Life-Threatening Adenovirus Infection
GlobeNewswire - Fri Mar 14, 7:14PM CDT
Chimerix, Inc. (Nasdaq:CMRX) today issued a statement thanking the U.S. Food and Drug Administration (FDA) for its collaboration in developing a protocol for the immediate initiation of a 20-patient pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients.
Strength Seen in Chimerix (CMRX): Stock Soars 18.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:04AM CDT
Chimerix, Inc. was a big mover last session, as the company saw its shares rise over 18% on the day.
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Chimerix to Provide Brincidofovir to Josh Hardy as First Patient in New Open-Label Study in Patients With Adenovirus Infections
GlobeNewswire - Tue Mar 11, 6:57PM CDT
Chimerix, Inc. (Nasdaq:CMRX) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) for the immediate initiation of a pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients. FDA has committed to work expeditiously with Chimerix on the design of a pivotal Phase 3 study that would be a continuation of this pilot study. Josh Hardy's story brought to public attention the often-devastating impact of adenovirus infection, and helped accelerate a discussion between the FDA and Chimerix regarding the need for additional clinical development to assess brincidofovir's potential in adenovirus infection. This study is expected to begin with Josh Hardy as the first patient enrolled on Wednesday, March 12, 2014.
Chimerix Announces Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Fri Mar 07, 6:08AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results for the fourth quarter and full year 2013.
Chimerix's Brincidofovir (CMX001) Safety and Antiviral Data Presented at 2014 BMT Tandem Meetings
GlobeNewswire - Fri Feb 28, 10:15AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today released data from presentations at the 2014 BMT Tandem Meetings related to its investigational antiviral with broad-spectrum activity, brincidofovir (CMX001). Brincidofovir's antiviral activity against adenovirus (AdV) and its pediatric safety and tolerability data from a randomized, controlled clinical study and Chimerix's expanded access program were presented on Thursday, February 27, 2104 during the Supportive Care Oral Abstracts Session. Brincidofovir is an investigational oral nucleotide analog in Phase 3 development, currently enrolling adult hematopoietic cell transplant (HCT) recipients in the SUPPRESS trial for the prevention of cytomegalovirus infection, with secondary endpoints including clinical and virologic evidence of DNA viral infections, including AdV, BK virus and other herpes viruses such as HHV-6 and varicella zoster virus that contribute to morbidity and mortality in the first year following HCT.
Chimerix (CMRX) Jumps: Stock Adds 6.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:51AM CST
Chimerix, Inc. was a big mover last session, as its shares rose just nearly 7% on the day.
Chimerix to Announce Fourth Quarter Financial Results on March 7, 2014
GlobeNewswire - Thu Feb 27, 6:45AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today that it will report financial results for the fourth quarter ended December 31, 2013, on Friday, March 7, 2014, before the market opens. Chimerix's management team will host a live conference call and audio webcast at 8:30 a.m. ET on Friday, March 7, 2014 to discuss the Company's results in detail.
Chimerix to Present at the Cowen 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 3:33PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that Kenneth I. Moch, President and CEO of Chimerix, will present at the Cowen 34 Annual Health Care Conference on Tuesday, March 4, 2014 at 10:40am EST at the Boston Marriott Copley Place in Boston.
Chimerix's Brincidofovir (CMX001) Selected for Two Oral Presentations at the 2014 BMT Tandem Meetings
GlobeNewswire - Fri Feb 21, 3:15PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced two oral presentations related to its broad-spectrum investigational antiviral, brincidofovir (CMX001), at the BMT Tandem Meetings being held February 26 - March 2, 2014 in Grapevine, Texas. The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT).
Chimerix to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 4:12PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that Kenneth I. Moch, President and CEO of Chimerix, will present at the 16 Annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 4:30pm EST at the Waldorf Astoria in New York City.
CareFusion Initiated at Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 1:50PM CST
Although CFN is well positioned to benefit from current trends in healthcare, we are concerned about continued pressure on margins and the effect of the transition of product line to Pyxis ES platform.
Financial Results, Conference Presentation Schedule, Clinical Trial Initiation, Recognition, and Dividend Payment - Research Report on Cantel, Chimerix, Verastem, Amedisys, and Ensign Group
PR Newswire - Wed Dec 25, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.